Dr. Parekh on Using Genomics in Multiple Myeloma Treatment

Video

In Partnership With:

Samir Parekh, MBBS, discusses using genomics to treat patients with multiple myeloma.

Samir Parekh, MBBS, associate professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai Hospital, discusses using genomics to treat patients with multiple myeloma.

Physicians are using genomics to identify new drivers to understand myeloma better, find treatment for patients, and find the impact of genomics of the tumor on the tumor microenvironment, explains Parekh. For prognosis, physicians are looking at RNA expression patterns to build a new map of myeloma and find parts of the map associated with poor-risk myeloma, says Parekh.

For immunology, neoantigens can be used to treat patients and track their disease, as these tumor mutations elicit responses that can be the most direct measure of the immunotherapies that are being used in myeloma, including immunomodulatory agents and monoclonal antibodies, concludes Parekh.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute